First-Line Therapy with Sunitinib in Advanced Renal Cell Carcinoma: Interpretation of the Overall Survival Data from ASCO 2008

[摘要]  Sunitinib is an oral multi-targeted receptor tyrosine kinase inhibitor of VEGFR and PDGFR that has become a new standard of care in the management of metastatic renal cell carcinoma (RCC).  Motzer et al first presented the results of a pivotal, phase III, multi-centre trial in metastatic RCC comparing Sunitinib to Interferon alfa at ASCO 2006 and the data was subsequently published in January 2007 1,2 . This study randomized previously untreated patients with metastatic clear cell carcinoma to either Sunitinib (50 mg once a day orally for 4 weeks followed by a 2-week break) or Interferon alfa (9 MU subcutaneously 3 times a week).  The primary endpoint was progression free-survival (PFS) and secondary endpoints included overall survival (OS), RECIST objective response rates, patient-reported outcomes and safety.

[学科分类] 肿瘤学